Clinical significance of the ratio between FOXP3 positive regulatory T cell and interleukin-17 secreting cell in renal allograft biopsies with acute T-cell-mediated rejection

Immunology

Volumn 136, Issue 3, 2012, Pages 344-351

  Chung, Byung H ^a   Oh, Hye J ^b   Piao, Shang G ^a   Hwang, Hyeon S ^a   Sun, In O ^a   Choi, Sun R ^a   Park, Hoon S ^a   Choi, Bum S ^a   Choi, Yeong J ^a   Park, Cheol W ^a   Kim, Yong Soo ^a   Cho, Mi La ^a,b   Yang, Chul W ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acute T cell mediated rejection; FOXP3; Interleukin 17; Regulatory T cell; T helper type 17

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 17; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ACUTE T CELL MEDIATED REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY TUBULE DISORDER; LONG TERM SURVIVAL; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE;

ACUTE DISEASE; ADULT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84861753772     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03588.x     Document Type: Article

References (35)

1. + regulatory T cells. Nat Immunol 2003; 4:330-6.
2. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
3. + regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 179:4901-9.
4. + regulatory T cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008; 19:2020-6.
5. Zuber J, Brodin-Sartorius A, Lapidus N et al. FOXP3-enriched infiltrates associated with better outcome in renal allografts with inflamed fibrosis. Nephrol Dial Transplant 2009; 24:3847-54.
6. + cells in renal allografts during acute rejection. Am J Transplant 2007; 7:914-22.
7. Bunnag S, Allanach K, Jhangri GS et al. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am J Transplant 2008; 8:1423-33.
8. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148:32-46.
9. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27:485-517.
10. H2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139-45.
11. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009; 9:883-9.
12. Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol 2008; 28:660-70.
13. + T lymphocytes and its regulation by protein kinase A pathway. Cytokine 1999; 11:257-66.
14. pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112:2340-52.
15. Voo KS, Wang Y, Santori FR et al. Identification of IL-17-producing FOXP3 regulatory T cells in humans. Proc Natl Acad Sci USA 2009; 106:4793-8.
16. Lee YK, Mukasa R, Hatton RD, Weaver CT. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009; 21:274-80.
17. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford) 2009; 48:602-6.
18. Ochs HD, Oukka M, Torgerson TR. TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol 2009; 123:977-83, quiz 84-5.
19. + regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010; 30:80-9.
20. + Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol 2010; 135:108-17.
21. Ratajczak P, Janin A, Peffault de Latour R et al. Th17/Treg ratio in human graft-versus-host disease. Blood 2010; 116:1165-71.
22. Cheng X, Yu X, Ding YJ et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008; 127:89-97.
23. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518-26.
24. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-14.
25. Lee SY, Chung BH, Piao SG et al. Clinical significance of slow recovery of graft function in living donor kidney transplantation. Transplantation 2010; 90:38-43.
26. Bock HA. Steroid-resistant kidney transplant rejection: diagnosis and treatment. J Am Soc Nephrol 2001; 12(Suppl. 17):S48-52.
27. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.
28. Deteix C, Attuil-Audenis V, Duthey A et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol 2010; 184:5344-51.
29. Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197:322-32.
30. Healy DG, Watson RW, O'Keane C et al. Neutrophil transendothelial migration potential predicts rejection severity in human cardiac transplantation. Eur J Cardiothorac Surg 2006; 29:760-6.
31. Sis B, Campbell PM, Mueller T et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7:1743-52.
32. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008; 8:492-6.
33. Steinmetz OM, Lange-Hsken F, Turner J et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007; 84:842-50.
34. Bluestone JA, Liu W, Yabu JM et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8:2086-96.
35. H17 cells. Nature 2007; 448:484-7.